The findings demonstrated that PAX6-knockdown LECs were more sensitive to travoprost than normal LECs, and offer important experimental evidence to develop pharmacological strategies for treating patients with congenital aniridia complicated by glaucoma. This evidence concerns the gene PAX6 and isolated aniridia.